GENERAL28 Sept 2026
Morepen Laboratories files its first US ANDA for sitagliptin tablets
Morepen Laboratories has filed its first ANDA (Abbreviated New Drug Application) in the US for sitagliptin tablets in three strengths. This moves the company beyond making active ingredients and contract manufacturing into finished-dose development, bioequivalence and analytical validation. For Indian pharma suppliers, it shows the shift from raw material supply to full finished products for regulated markets.
Key Statutory Highlights
- Morepen Laboratories has filed its first US ANDA for sitagliptin tablets in three strengths.
- The filing marks Morepen's entry into integrated finished-dose development and regulatory filings in the US market.
- The submission expands Morepen's existing API (active pharmaceutical ingredient) and CDMO (contract development and manufacturing organisation) capabilities to include formulation development, bioequivalence and analytical validation.
Actionable Advice for Taxpayers / Founders:If you run a pharma ingredients or contract manufacturing business, it may be worth reviewing whether your current capabilities can be extended into finished-dose development for regulated markets, and speaking to a regulatory consultant before investing.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: